Journal article icon

Journal article

Proneural–mesenchymal hybrid glioblastoma cells are resistant to therapy and dependent on nuclear import

Abstract:
Background: Despite extensive research efforts, glioblastoma (GBM) remains a deadly disease with poor prognosis. Although previous studies have identified various cell states within GBM tumors, the molecular mechanism underlying adaptive GBM cell plasticity induced by conventional therapy remains unclear. Methods: We used fluorescent reporters for proneural (PN) and mesenchymal (MES) subtypes to monitor GBM cell plasticity in real-time across multiple patient-derived cell lines. This approach revealed cells that concurrently expressed both PN and MES markers. To investigate this unique hybrid population, we implemented a comprehensive methodological approach encompassing bulk and single-cell RNA sequencing, single-cell ChIP sequencing, nuclear proteomics, high-resolution imaging, orthotopic mouse models, clinical dataset analysis, and pharmacological and genetic techniques. This multifaceted strategy allowed us to gain functional and molecular insights into this distinct cellular population. Results: We showed that these hybrid cells are increased by conventional therapies, and are resistant to these therapies. At the molecular level, hybrid cells display significant alterations in chromatin structure and nuclear protein composition, elevated transcriptional activity, Myc activation, and improved transport between the nucleus and cytoplasm. Genetic and pharmaceutical inhibition of the nuclear import/export shuttling machinery, increased in hybrid cells, effectively suppressed adaptive GBM cell plasticity and hybrid identity, thereby enhancing the sensitivity of GBM cells to therapies. Conclusions: Our results indicate that GBM hybrid cells play a crucial role in chemoradiation resistance. The nuclear transport machinery presents a potential therapeutic target for hybrid cells, offering a way to counteract the typical resistance to treatment observed in GBM.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1093/neuonc/noaf160

Authors

More by this author
Role:
Author
ORCID:
0000-0003-3800-4077
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-8712-895X
More by this author
Role:
Author
ORCID:
0000-0002-7150-9758


More from this funder
Funder identifier:
10.13039/501100006364
Grant:
INCa-2020-1-PLBIO-01-ICR-1
More from this funder
Funder identifier:
10.13039/501100002915
Grant:
FRM N° DGE20111123020
More from this funder
Funder identifier:
https://ror.org/0472cxd90
Grant:
805225
More from this funder
Funder identifier:
https://ror.org/00rbzpz17


Publisher:
Oxford University Press
Journal:
Neuro-Oncology More from this journal
Volume:
27
Issue:
11
Pages:
2876-2893
Publication date:
2025-07-08
DOI:
EISSN:
1523-5866
ISSN:
1522-8517


Language:
English
Keywords:
Source identifiers:
3763618
Deposit date:
2026-02-16
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP